Abstract #0074
13 C MRS of hyperpolarized [1- 13 C] pyruvate can differentiate between SAHA resistant and sensitive glioblastoma cells
Pia Eriksson 1 , Myriam M Chaumeil 1 , Joydeep Mukherjee 2,3 , Russell O Pieper 2,3 , and Sabrina M Ronen 1,3
1
Radiology & Biomedical Imaging, University
of California San Francisco, San Francisco, CA, United
States,
2
Neurological
Surgery, University of California San Francisco, San
Francisco, CA, United States,
3
Brain
Tumor Research Center, University of California San
Francisco, CA, United States
Several currently available drugs with clinical
relevance to GBM affect pyruvate metabolism. In this
study, we show that
13
C
MRS of hyperpolarized [1-
13
C] pyruvate can
also be used to evaluate response to the previously
unexplored drug SAHA in glioblastoma cells. In GBM14
SAHA-sensitive cells, a drop in hyperpolarized [1-
13
C]
pyruvate to [1-
13
C] lactate conversion was
observed after SAHA treatment, while it remained
unchanged in SAHA-resistant cells. Furthermore,
hyperpolarized [1-
13
C] lactate levels were
significantly different between sensitive and resistant
cells both pre- and post-treatment, indicating that this
metabolic imaging technique might also have prognostic
value.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
